<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838769</url>
  </required_header>
  <id_info>
    <org_study_id>U0693</org_study_id>
    <nct_id>NCT04838769</nct_id>
  </id_info>
  <brief_title>REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men</brief_title>
  <acronym>VAPEUR RCT</acronym>
  <official_title>Water Vapor Thermotherapy vs. Combination Pharmacotherapy for Symptomatic Benign Prostatic Hyperplasia Refractory to Alpha Blocker Monotherapy in Sexually Active Men: A Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to compare water vapor thermotherapy with the REZŪM™ System to dual&#xD;
      drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to&#xD;
      alpha-blocker monotherapy in sexually active men.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVE - To compare water vapor thermotherapy with the REZŪM™ System to dual drug&#xD;
      therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to&#xD;
      alpha-blocker monotherapy in sexually active men.&#xD;
&#xD;
      STUDY DESIGN - Multicenter open-label randomized controlled parallel-group post-market trial.&#xD;
&#xD;
      STUDY TREATMENTS AND RANDOMIZATION - Subjects will be randomly assigned to REZŪM or dual drug&#xD;
      therapy treatments; 1:1 randomization via the electronic data capture (EDC) system. Both&#xD;
      treatments are commercially available. Subjects randomized to receive the REZŪM treatment&#xD;
      will receive standardized treatment and subjects randomized to dual drug therapy will receive&#xD;
      the local formulary preferred choice of urinary selective alpha blocker and 5-alpha reductase&#xD;
      inhibitor.&#xD;
&#xD;
      VISIT SCHEDULE - Study visits are at: enrollment/baseline, treatment, 3 months, 6 months, and&#xD;
      yearly follow-up through 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Prostate Symptom Score (IPSS) change</measure>
    <time_frame>From Baseline to 12 months</time_frame>
    <description>Primary Statistical Hypothesis: Change in IPSS score will be compared between groups. IPSS score ranges from 0 to 35 with higher scores indicating worse symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Male Sexual Health Questionnaire (MSHQ) total score change</measure>
    <time_frame>From Baseline to 12 months</time_frame>
    <description>Change in MHSQ score will be compared between groups. MHSQ score ranges from 0 to 125 with higher scores indicating better outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>End of available follow-up, up to 24 months</time_frame>
    <description>Disease progression, defined as occurrence of any of the following:&#xD;
Surgical retreatment for LUTS/BPH&#xD;
Urinary retention requiring urinary catheterization after 90 days post-treatment&#xD;
IPSS increase from baseline by ≥ 4 points&#xD;
Introduction of a new drug agent to treat LUTS/BPH</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">394</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>REZŪM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use (IFU). The REZŪM System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with benign prostatic hyperplasia (BPH). It is indicated for men with a prostate volume ≥ 30 ml. The REZŪM System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe.&#xD;
1:1 randomization will occur via the electronic data capture (EDC) system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual Drug Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>REZŪM</intervention_name>
    <description>Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.</description>
    <arm_group_label>REZŪM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha blocker and 5-alpha reductase inhibitor</intervention_name>
    <description>Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.</description>
    <arm_group_label>Dual Drug Therapy</arm_group_label>
    <other_name>Dual Drug Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sexually active male subjects ≥ 45 years of age who have persistent non-neurogenic&#xD;
             lower urinary tract symptoms refractory to first-line treatment with single agent&#xD;
             Alpha Adrenoceptor Antagonist therapy&#xD;
&#xD;
          2. Subject is willing and able to answer all domains of MSHQ&#xD;
&#xD;
          3. IPSS score ≥ 13 within 6 months prior to enrollment&#xD;
&#xD;
          4. Peak urinary flow rate (Qmax): ≥ 5ml/sec to ≤ 15 ml/sec with minimum voided volume of&#xD;
             ≥ 150 ml within 6 months prior to enrollment on two separate measurements&#xD;
&#xD;
          5. Post-void residual (PVR) ≤250 ml within 6 months prior to enrollment&#xD;
&#xD;
          6. Prostate volume ≥ 30 ml as measured by transrectal ultrasound within 3 months prior to&#xD;
             enrollment&#xD;
&#xD;
          7. Subject is willing and capable of providing informed consent&#xD;
&#xD;
          8. Subject is willing and capable of participating in all visits associated with this&#xD;
             study at an approved clinical study site and at the intervals defined by this Clinical&#xD;
             Investigational Plan (CIP)&#xD;
&#xD;
          9. France subjects only: subjects must be affiliated to national security insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to participate in full duration of study&#xD;
&#xD;
          2. Prior surgical treatment for BPH&#xD;
&#xD;
          3. Increased risk of bleeding&#xD;
&#xD;
          4. Presence of Genitourinary Cancer or other pelvic cancer&#xD;
&#xD;
          5. Functional issues with bladder&#xD;
&#xD;
          6. Presence of active infection in genitourinary tract&#xD;
&#xD;
          7. Structural and Anatomic issues with urinary tract and renal function&#xD;
&#xD;
          8. Concomitant Drug Therapy&#xD;
&#xD;
          9. Temporal restraints and risks for general anaesthesia or comorbidity that would&#xD;
             elevate risk of participation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Sexually active male subjects</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Romain Mathieu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes, Hôpital Pontchaillou</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evanguelos Xylinas, Ass. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Bichat</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Beaudoint</last_name>
    <phone>+32479904163</phone>
    <email>Caroline.Beaudoint@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Teresa Takle-Flach</last_name>
    <phone>+19529306000</phone>
    <email>Teresa.Takle-Flach@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier du Pays d'Aix</name>
      <address>
        <city>Aix-en-Provence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Fourmarier, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Hilaire</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ismaël Galliot, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Privé Saint Grégoire</name>
      <address>
        <city>Saint-Grégoire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>REZŪM</keyword>
  <keyword>Water vapor thermotherapy</keyword>
  <keyword>Lower urinary tract symptoms</keyword>
  <keyword>BPH</keyword>
  <keyword>LUTS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic alpha-Antagonists</mesh_term>
    <mesh_term>5-alpha Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

